Purpose: Alternative splice isoforms of TCF4, a gene implicated in Fuchs corneal dystrophy, have been identified in multiple human tissues outside of the eye. The aim of this study was to identify the transcriptional profile of TCF4 in the corneal endothelium.
T he corneal endothelium is a single monolayer that lines the posterior cornea. It contributes barrier and pump functions through maintenance of tight junctions and solute pumps, which contribute to corneal clarity. Loss of the corneal endothelium, such as occurs in Fuchs endothelial corneal dystrophy (FECD), results in corneal edema. 1, 2 This condition, the most frequent indication for endothelial keratoplasty performed in the United States, 3 demonstrates early changes in the corneal endothelium and progresses to affect the entire cornea in later stages of the disease.
The significance of TCF4 in corneal endothelial (CE) function is evidenced by its disruption in FECD. After identification of 4 FECD loci, FCD1-4, [3] [4] [5] [6] and causal mutations in SLC4A11, TCF8, LOXHD1, and AGBL1, 6-9 TCF4 was implicated in Fuchs dystrophy pathogenesis through a strong association with expansion of a trinucleotide (CTG) repeat, [10] [11] [12] [13] a pattern replicated in multiple cohorts of varying ethnic backgrounds. [14] [15] [16] However, next-generation sequencing of the complete TCF4 gene was unable to detect any variant that could explain the genetic etiology of FECD in these cases. 17 Our recent analysis of a large cohort of late-onset FECD cases confirmed a strong association with TCF4 trinucleotide repeat expansion in hundreds of cases and controls. 18 Further functional studies have identified sequestration of splicing proteins by expansion of CTG repeats that results in missplicing of several TCF4 transcripts and RNA toxicity in Fuchs dystrophy. 19, 20 Given the discrete contribution of the TCF4 locus to a late-onset disorder, we wanted to determine the transcriptional profile of this locus in the corneal endothelium.
METHODS

Donor Cornea Specimens
Three donor corneas (2 men and 1 woman; age: .60 years) were obtained from the Keralink Eye Bank (Baltimore, MD), with a maximum of 24-hour death-to-preservation time, containing not less than 1800 CE cells per square millimeter. Corneas were transported in Optisol, and Descemet membrane was removed for RNA isolation.
Genotyping of CTG18.1 Allele
The trinucleotide repeats in intron 3 of TCF4 were determined by short tandem repeat and triplet repeat primed polymerase chain reaction (PCR) assays as described. 18 The PCR products were run on ABI3730, and fragment analysis was performed with Gene Mapper software (Applied Biosystems Inc, Foster City, CA).
RNA Isolation and 59 RACE
The corneal endothelium isolated by dissection of the normal donor cornea was lysed and homogenized in 250 mL of Trizol (ThermoFisher Scientific, Waltham, MA). Trizol (750 mL) was added after homogenization following the manufacturer's RNA extraction protocol. Finally, RNA was resuspended in 30 mL of RNase-free water.
RNA from an immortalized CE cell line 21 was extracted from 1 · 10 6 cells using Trizol and resuspended in 50 mL of RNase-free water. To identify the isoforms of TCF4, RNA was extracted (Trizol, Sigma-Aldrich, St. Louis, MO) from the corneal endothelium of a postmortem eye (man aged 70 years) obtained from the eye bank (Keralink, Baltimore, MD) with 14-hour death-to-preservation time and 7 days from preservation to use. 59 rapid amplification of cDNA ends (RACE) was performed with 0.5 mg of RNA as a starting material as per the manufacturer's instructions using the GeneRacer Kit (ThermoFisher Scientific, Philadelphia, PA). The cDNA obtained by RACE was used as a template for PCR reactions with a forward primer (provided in the kit) that binds the ligated 59 RNA adapter and TCF4 specific reverse primers (59-GTCTGCTGAGGAGTGTGATGGATAG-39 and 59-CATA-GACTGAAGATGGCAAACCTGG-39) that span exon 11 and exons 8 and 9. The 2 independent PCR reactions were ligated with the pCR4TOPO vector. The bacterial colonies were screened by digesting miniprep DNA with EcoRI, and the positive clones were sequenced with M13 primers by Sanger sequencing. The sequences were compared with the RefSeq and predicted isoforms in the UCSC Genome Browser.
Analysis of TCF4 Isoforms
Expression of TCF4 isoform 7b, exons 16 to 19 representing total TCF4, and GAPDH was tested in a panel of cDNA from multiple human tissues (Human MTC Panel I, Clontech, Cat. No. 636742), CE and retinal pigment epithelial (RPE) cell lines; PCR primers are listed in Supplemental Digital Content 1 (see Table S1 , http://links.lww.com/ICO/A621). The following PCR cycle was used to amplify TCF4 exons 16 to 19 and GAPDH; 95°C for 2 minutes and cycled 35 times at 95°C for 20 seconds; 58°C for 25 seconds; 68°C for 1 minute; and 68°C for 2 minutes as the final extension with LaTaq polymerase (Takara Bio, Kusatsu, Japan). TCF4 isoform 7b was amplified at 95°C for 2 minutes; cycled 35 times at 95°C for 20 seconds; 64°C for 25 seconds; and 68°C for 40 seconds; 68°C for 2 minutes as the final extension. Real-time PCR (RT-PCR) analysis to test relative expression of isoform 7b was performed with Power Sybr Green PCR Master Mix (ThermoFisher Scientific) in a reaction volume of 10 mL and 250 nM final concentration of each primer. The threshold C T of TCF4 isoform 7b was normalized with GAPDH tested with a TaqMan assay (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/ICO/A621). The relative fold change was calculated based on 2^(-dC T ) of normalized expression.
To analyze isoforms for which a predesigned TaqMan assay was not available, the Custom TaqMan assay design tool (ThermoFisher Scientific) along with bioinformatics analyses (Custom Plus) was used. The 25bp sequence for the location of probes and assay IDs have been listed in Supplemental Digital Content 1 (see Table S1 , http://links.lww.com/ICO/A621). PCR reactions with appropriate TaqMan assay probes and primers mixed with cDNA and 2X TaqMan Gene Expression master mix (ThermoFisher Scientific) were performed in duplicate. The dC T of each TCF4 isoform-specific TaqMan assay was derived by normalizing with the average C T of GAPDH. Relative expression (dCt) of each TCF4 isoform was expressed as 2^(-dC T ). This value from 1 control donor sample was converted to a fold change of 1.0, and the fold change of other samples was calculated relative to 1.0.
RESULTS
The aim of this study was to identify the isoforms of TCF4 that are expressed in the corneal endothelium. Alternative splice isoforms of TCF4 have been identified in multiple human tissues, 22 excluding those from the eye.
Therefore, we extracted RNA from the donor corneal endothelium and performed rapid amplification of cDNA ends. Because the previously reported alternatively spliced isoforms of TCF4 differed significantly on the 59 exons, we used a forward primer that binds the 59RACE adapter and 2 reverse primers within exon 11 and exon 8 to 9 in independent PCR reactions (Methods). Subsequent to sequencing and analysis of 83 bacterial colonies, resultant of transformation of the multiple PCR products specific to TCF4, we identified a total of 11 different transcripts that included 7 mutually exclusive 59 exons; some of them shared the same 59 exon but different downstream exons, as exemplified by isoforms 2a and 3a ( Fig. 1 and see Figure S1 , Supplemental Digital Content 2, http://links.lww.com/ICO/A622). Of 11 isoforms, the first exon of the 9 transcripts (2a, 2b, 3a, 3b, 3c, 3d, 4a, 7a , and 9a) is annotated as an exon according to the UCSC Genome Browser. We compared sequences of 59 ends of the isoforms of TCF4 with those of the primer sequences reported by Sepp et al 22 and identified isoform 7c that was reported in this study. We also identified isoform 7b that is not annotated as an isoform in the UCSC Genome Browser and not reported in the literature.
We tested the expression pattern of isoform 7b in a panel of cDNA derived from multiple human tissues and included cDNA from CE and RPE cell lines. RT-PCR of cDNA from these multiple sources suggested elevated expression of TCF4 isoform 7b specifically in the corneal endothelium and placenta ( Fig. 2A) , whereas amplification of exons 16 to 19 of TCF4, suggestive of the total pool of TCF4 transcripts, showed equal expression similar to GAPDH. Differential expression of isoform 7b was further confirmed by RT-PCR analysis of the cDNA samples (Fig. 2B) and suggested a similar pattern of expression as observed in Figure 2A . It is to be noted that expression of this isoform is 10-fold higher in a CE cell line than in its nearest neighboring cell type (RPE), further suggesting the specificity of its expression.
We were intrigued by this complex alternative splicing and determined whether all the above-identified transcripts would be capable of producing a relevant protein. Analysis of these isoforms in the UCSC Genome Browser suggested potential translation start sites within exon 2 and the first codon of exons 3 and 7. The first exons of isoforms 4a and 9a possess a translation start site as well and are in frame with the first codons on exons 4 and 9. Therefore, analysis of all the above-identified transcripts suggests that they can be potentially translated into functional proteins. Moreover, analysis of possible open reading frames in the first exon isoform 7b revealed a translation start site, resulting in a protein sequence MVMAE, followed by an in-frame first codon in exon 7, which suggests yet another functional transcript of TCF4.
To further delineate differential expression of TCF4 splice variants that span CTG18.1, we analyzed expression of 6 alternative splice isoforms that are transcribed from either exon 2 or 3 in RNA extracted from the corneal endothelium Custom TaqMan assays were designed to specifically distinguish between the 6 isoforms being tested (see Table S2 , Supplemental Digital Content 1, http://links.lww.com/ICO/A621). We also included an additional TaqMan assay that detected the last 2 exons of TCF4, which helps detect the complete pool of the TCF4 transcript. We detected expression of all 6 TCF4 isoforms in all donor corneas (controls) and the CE cell line. Relative expression of the 6 isoforms in the controls suggested a similar level of expression of isoforms 2a and 3a, followed by 3c and 3d and comparatively very low levels of 2b and 3b (Fig. 3) . Relative expression of the total pool of the TCF4 transcript assayed with a primer and probe that spans exons toward the 39 end of the transcripts common to most TCF4 isoforms showed increased variability within normal donor control RNA (0.36-1.00-fold change), and CE cell line (Control-4) expressed the least with a relative fold change of 0.23.
DISCUSSION
In this study, we have identified multiple isoforms of TCF4 in the corneal endothelium, including a novel isoform that was expressed in the normal control endothelium and its detection replicated in a CE cell line.
TCF4 spans a 443-kb genomic fragment on chromosome 18, and the full-length transcript (NM_001243226) comprises 20 coding exons. The diversity of TCF4 expression emerges not only from the alternatively spliced transcripts with variable lengths but also from generating multiple first exons that vary with each isoform, adding complexity to expression. 22 Some of these isoforms share the same first exon but may be different with their composition of downstream exons. Sepp et al 22 have identified a range of TCF4 isoforms and analyzed expression of each of these isoforms in multiple human tissues, although not the eye, suggesting tissue specificity of certain isoforms.
We demonstrate that consistent with what has been observed in other tissues, TCF4 expression in the corneal endothelium follows a complex pattern. In this study, we have identified TCF4 isoforms from the corneal endothelium of a 70-year-old donor, while the susceptibility and progression of FECD occurs typically in the fourth and fifth decades of life. It is possible that expression of TCF4 and processing of its alternative splice variants may undergo modifications with age. We sequenced a total of 83 clones and terminated further screening of clones because of the redundancy of the identified transcripts. It is likely that some of the known transcripts were not sequenced with this approach. Investigations to probe RNA-seq results and analyze transcriptomic reads for isoforms in FECD specimens with known trinucleotide repeat expansion may be warranted to expand our understanding of the role of TCF4 in pathogenesis of FECD.
In conclusion, we have analyzed the transcriptional profile of TCF4 in the corneal endothelium and show that multiple isoforms of TCF4 are expressed therein. The complexity of TCF4 expression requires further probing to understand the effect of the protein function and its role in FECD. 
